$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000139047816000110 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$0.00	$2.750M
YoY Change	-100.0%	26.55%
Cost Of Revenue		$393.0K
YoY Change		18.73%
Gross Profit		$2.357M
YoY Change		27.96%
Gross Profit Margin		85.71%
Selling, General & Admin	$3.525M	$3.087M
YoY Change	14.19%	-54.8%
% of Gross Profit		130.97%
Research & Development	$5.443M	$5.825M
YoY Change	-6.56%	-13.96%
% of Gross Profit		247.14%
Depreciation & Amortization	$6.000K	$98.00K
YoY Change	-93.88%	-57.76%
% of Gross Profit		4.16%
Operating Expenses	$8.968M	$8.912M
YoY Change	0.63%	-34.47%
Operating Profit	-$8.968M	-$8.912M
YoY Change	0.63%	-24.79%
Interest Expense	-$3.960M	$930.0K
YoY Change	-525.81%	-90.19%
% of Operating Profit
Other Income/Expense, Net	-$170.0K	-$321.0K
YoY Change	-47.04%	-87.34%
Pretax Income	-$13.10M	-$8.310M
YoY Change	57.64%	227.17%
Income Tax
% Of Pretax Income
Net Earnings	-$16.49M	-$10.54M
YoY Change	56.52%	315.5%
Net Earnings / Revenue		-383.16%
Basic Earnings Per Share	-$1.84	-$0.08
Diluted Earnings Per Share	-$1.649B	-$1.831B
COMMON SHARES
Basic Shares Outstanding	8.969M shares	133.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.70M	$52.90M
YoY Change	-34.4%	0.95%
Cash & Equivalents	$34.71M	$52.86M
Short-Term Investments
Other Short-Term Assets	$3.300M	$2.800M
YoY Change	17.86%	86.67%
Inventory		$637.0K
Prepaid Expenses
Receivables		$1.060M
Other Receivables		$0.00
Total Short-Term Assets	$37.95M	$57.32M
YoY Change	-33.8%	2.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$299.0K	$528.0K
YoY Change	-43.37%	-19.14%
Goodwill	$5.898M	$6.069M
YoY Change	-2.82%	2.9%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$8.200M
YoY Change	-98.78%	8100.0%
Total Long-Term Assets	$28.42M	$51.29M
YoY Change	-44.59%	40.47%
TOTAL ASSETS
Total Short-Term Assets	$37.95M	$57.32M
Total Long-Term Assets	$28.42M	$51.29M
Total Assets	$66.37M	$108.6M
YoY Change	-38.89%	17.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.019M	$3.293M
YoY Change	-69.06%	109.21%
Accrued Expenses	$4.042M	$12.15M
YoY Change	-66.73%	24.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.740M	$3.994M
YoY Change	-6.36%	28.76%
Total Short-Term Liabilities	$42.22M	$33.96M
YoY Change	24.31%	26.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.534M
YoY Change	-100.0%	-48.66%
Other Long-Term Liabilities	$6.300M	$7.000M
YoY Change	-10.0%	0.0%
Total Long-Term Liabilities	$6.300M	$3.534M
YoY Change	78.27%	-48.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.22M	$33.96M
Total Long-Term Liabilities	$6.300M	$3.534M
Total Liabilities	$53.95M	$49.52M
YoY Change	8.94%	8.16%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$312.1M	$289.0M
YoY Change	8.02%	24.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M
YoY Change	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares
Shareholders Equity	$12.41M	$59.08M
YoY Change
Total Liabilities & Shareholders Equity	$66.37M	$108.6M
YoY Change	-38.89%	17.68%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$16.49M	-$10.54M
YoY Change	56.52%	315.5%
Depreciation, Depletion And Amortization	$6.000K	$98.00K
YoY Change	-93.88%	-57.76%
Cash From Operating Activities	-$13.22M	-$11.56M
YoY Change	14.36%	43.59%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$18.00K
YoY Change	-66.67%	-18.18%
Acquisitions
YoY Change
Other Investing Activities	-$1.050M
YoY Change
Cash From Investing Activities	-$1.056M	-$518.0K
YoY Change	103.86%	-74.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$20.19M	$42.12M
YoY Change	-52.07%
Debt Paid & Issued, Net	$1.030M	$947.0K
YoY Change	8.76%	31466.67%
Cash From Financing Activities	$19.25M	$41.28M
YoY Change	-53.37%	180.46%
NET CHANGE
Cash From Operating Activities	-$13.22M	-$11.56M
Cash From Investing Activities	-$1.056M	-$518.0K
Cash From Financing Activities	$19.25M	$41.28M
Net Change In Cash	$4.979M	$29.21M
YoY Change	-82.95%	529.53%
FREE CASH FLOW
Cash From Operating Activities	-$13.22M	-$11.56M
Capital Expenditures	$6.000K	$18.00K
Free Cash Flow	-$13.22M	-$11.57M
YoY Change	14.24%	43.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	321000	USD
CY2016Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	170000	USD
CY2016Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6312000	USD
CY2016Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	3872000	USD
CY2015Q4	gale	Contract Research Payable ContractResearchPayable	3294000	USD
CY2015Q1	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	145000	shares
CY2015Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6142000	USD
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	181837117	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
CY2016Q1	dei	Trading Symbol TradingSymbol	GALE
CY2015Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	1151000	USD
CY2016Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-3872000	USD
CY2015Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-321000	USD
CY2016Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-170000	USD
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
CY2016Q1	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	31000	shares
CY2016Q1	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	13643000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2016Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	461000	shares
CY2016Q1	gale	Contract Research Payable ContractResearchPayable	2437000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2015Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-279383000	USD
CY2016Q1	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-295876000	USD
CY2016Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	4266000	USD
CY2016Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y10M14D
CY2016Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
CY2016Q1	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
CY2015Q1	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	46000	USD
CY2015Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10296000	USD
CY2016Q1	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	5590000	USD
CY2015Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	14518000	USD
CY2016Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	23934000	USD
CY2015Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	14518000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29730000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34709000	USD
CY2016Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	23934000	USD
CY2016Q1	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	5590000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2015Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2016Q1	gale	Gale401rights GALE401rights	9255000	USD
CY2015Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2016Q1	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2015Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	-1152000	USD
CY2016Q1	gale	Loss On Warrant Exchange LossOnWarrantExchange	3873000	USD
CY2015Q1	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2015Q1	gale	Numberof Shares Per Unit NumberofSharesPerUnit	0.50	shares
CY2016Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	9399000	shares
CY2016Q1	gale	Paymentson Disposalof Productive Assets PaymentsonDisposalofProductiveAssets	1050000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	5400000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	40800000	USD
CY2016Q1	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	20200000	USD
CY2014Q4	gale	Purchase Agreement Term PurchaseAgreementTerm	P36M
CY2016Q1	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	46000	USD
CY2016Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	25000	USD
CY2016Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue		USD
CY2015Q1	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	1826923	shares
CY2015Q2	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	3653846	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1597000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1019000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5292000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4042000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	942000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	296730000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312120000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	656000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5590000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33229000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47776000	shares
CY2015Q4	us-gaap	Assets Assets	82144000	USD
CY2016Q1	us-gaap	Assets Assets	66365000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	53621000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	37949000	USD
CY2015Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	392000	USD
CY2016Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	88000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23650000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52860000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	57636000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29210000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4979000	USD
CY2015Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-500000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1050000	USD
CY2015Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1059000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3475000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.47
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.08
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.42
CY2016Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.60	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1826923	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22308000	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	35775000	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3653846	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162581753	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182512117	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161906753	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	181837117	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	8912000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	8968000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30M
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5418000	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5418000	USD
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	171000	USD
CY2016Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	100000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1535000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	642000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2015Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
CY2016Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-20000000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-418000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	112000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	28000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	5898000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8306000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13102000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.06
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.07
CY2015Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2231000	USD
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3391000	USD
CY2015Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	25000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-578000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1885000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1250000	USD
CY2015Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-1172000	USD
CY2016Q1	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	84000	USD
CY2015Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	0	USD
CY2016Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-20000000	USD
CY2015Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	21700000	USD
CY2016Q1	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	1700000	USD
CY2015Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-225000	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-91000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	166000	USD
CY2016Q1	us-gaap	Interest Payable Current InterestPayableCurrent	21000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	68631000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	53952000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82144000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66365000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57071000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	42222000	USD
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5925000	USD
CY2016Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	4487000	USD
CY2015Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	25000000	USD
CY2016Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	USD
CY2016Q1	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	25000000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4739000	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3740000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41284000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19251000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-518000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1056000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11556000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13216000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10497000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9741000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-10537000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-16493000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8912000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8968000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-321000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-170000	USD
CY2015Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	606000	USD
CY2016Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4134000	USD
CY2015Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	500000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1398000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1051000	USD
CY2016Q1	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	20000000	USD
CY2015Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2000	USD
CY2016Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	21000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42121000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20189000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	38000000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	110000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	78000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	335000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	299000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	947000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1030000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5825000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5443000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	401000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	401000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3087000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3525000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	371000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	656000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7462
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7524
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7152000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.19
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1326000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	105000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.56
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	421000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13262000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12001000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.59
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	366000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.87
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.37
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.84
CY2015Q1	us-gaap	Share Price SharePrice	1.56
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2016Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2016Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.10
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24358974	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	19772727	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000	shares
CY2016Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	46000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	78000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21800000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20189000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13513000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	12413000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13513000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12413000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	136054864	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	179372320	shares
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">March 31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company’s cash equivalents were invested in money market mutual funds. The Company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div>
CY2016Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has recast the financial information for the three months ended March 31, 2015 to reflect the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001390478-16-000110-index-headers.html	Edgar Link	pending
0001390478-16-000110-index.html	Edgar Link	pending
0001390478-16-000110.txt	Edgar Link	pending
0001390478-16-000110-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20160331.xml	Edgar Link	completed
gale-20160331.xsd	Edgar Link	pending
gale-20160331x10q.htm	Edgar Link	pending
gale-20160331_cal.xml	Edgar Link	unprocessable
gale-20160331_def.xml	Edgar Link	unprocessable
gale-20160331_lab.xml	Edgar Link	unprocessable
gale-20160331_pre.xml	Edgar Link	unprocessable
gale20160331ex-102.htm	Edgar Link	pending
gale20160331ex-103.htm	Edgar Link	pending
gale20160331ex-104.htm	Edgar Link	pending
gale20160331ex101.htm	Edgar Link	pending
gale20160331ex311.htm	Edgar Link	pending
gale20160331ex312.htm	Edgar Link	pending
gale20160331ex321.htm	Edgar Link	pending
gale20160331ex41.htm	Edgar Link	pending
gale20160331ex42.htm	Edgar Link	pending
gale20160331ex43.htm	Edgar Link	pending
logo-verticala05.jpg	Edgar Link	pending
logo-verticala07.jpg	Edgar Link	pending
pipeline0304a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2016 Q1 Form 10-Q Financial Statement

#000139047816000110 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2016 Q1 Form 10-Q Financial Statement

#000139047816000110 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls